[go: up one dir, main page]

BG104076A - Combined treatment including amplodipin and a statine compound - Google Patents

Combined treatment including amplodipin and a statine compound

Info

Publication number
BG104076A
BG104076A BG104076A BG10407600A BG104076A BG 104076 A BG104076 A BG 104076A BG 104076 A BG104076 A BG 104076A BG 10407600 A BG10407600 A BG 10407600A BG 104076 A BG104076 A BG 104076A
Authority
BG
Bulgaria
Prior art keywords
combinations
pharmaceutically acceptable
patients
amplodipin
statine
Prior art date
Application number
BG104076A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jan Buch
Robert Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG104076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104076A publication Critical patent/BG104076A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
BG104076A 1997-08-29 2000-01-13 Combined treatment including amplodipin and a statine compound BG104076A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29
PCT/IB1998/001220 WO1999011263A1 (fr) 1997-08-29 1998-08-10 Therapie combinee comprenant de l'amlodipine et un compose de statine

Publications (1)

Publication Number Publication Date
BG104076A true BG104076A (en) 2000-09-29

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104076A BG104076A (en) 1997-08-29 2000-01-13 Combined treatment including amplodipin and a statine compound

Country Status (36)

Country Link
US (1) US20020025981A1 (fr)
EP (1) EP1003507A1 (fr)
JP (1) JP2001514224A (fr)
KR (1) KR20010022385A (fr)
CN (1) CN1117566C (fr)
AP (1) AP1207A (fr)
AR (1) AR017514A1 (fr)
AU (1) AU744982B2 (fr)
BG (1) BG104076A (fr)
BR (1) BR9811558A (fr)
CA (1) CA2296726C (fr)
CO (1) CO4970726A1 (fr)
DZ (1) DZ2600A1 (fr)
EA (1) EA002705B1 (fr)
GT (1) GT199800134A (fr)
HN (1) HN1998000124A (fr)
HR (1) HRP980475A2 (fr)
HU (1) HUP0003103A3 (fr)
ID (1) ID24275A (fr)
IL (2) IL133957A0 (fr)
IS (1) IS5345A (fr)
MA (1) MA26539A1 (fr)
NO (1) NO20000999L (fr)
NZ (1) NZ502283A (fr)
OA (1) OA11289A (fr)
PA (1) PA8457201A1 (fr)
PE (1) PE106999A1 (fr)
PL (1) PL339088A1 (fr)
SA (1) SA98190432A (fr)
SK (1) SK1392000A3 (fr)
TN (1) TNSN98158A1 (fr)
TR (1) TR200000562T2 (fr)
UY (1) UY25159A1 (fr)
WO (1) WO1999011263A1 (fr)
YU (1) YU2700A (fr)
ZA (1) ZA987843B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136233C (fr) 1992-05-19 2004-03-30 Graham Edmund Kelly Supplements contenant des phyto-oestrogenes, analogues ou metabolites de ces produits
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
DE69908643T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
EP1076091A1 (fr) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Composé ou composition pharmaceutique pour la prévention et/ou le traitement d'ischémie cardiaque, de maladies vasculaires périphériques, de tumeurs et de plaies
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
CA2420844A1 (fr) * 2000-08-30 2003-02-28 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
JP2005521653A (ja) 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (fr) * 2004-04-04 2005-10-20 Sepracor Inc. Combinaisons comprenant de la (s)-amlodipine et un inhibiteur de la hmg-coa reductase ou un inhibiteur de l'absorption de cholesterol ou les deux a la fois et methodes permettant de reduire l'hypertension
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
US8124622B2 (en) 2006-03-29 2012-02-28 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008023958A1 (fr) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Composition pharmaceutique combinée à libération contrôlée comprenant de la dihydropyridine, des bloqueurs de canal calcium et des inhibiteurs de l'hgm-coa réductase
WO2008023869A1 (fr) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. PRÉPARATION PHARMACEUTIQUE COMBINÉE À LIBÉRATION CONTRÔLÉE COMPRENANT DES INHIBITEURS CALCIQUES À BASE DE DIHYDROPYRIDINE ET DES INHIBITEURS DE HMG-CoA RÉDUCTASE
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR20090091085A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 약제학적 제제
WO2009125987A2 (fr) * 2008-04-10 2009-10-15 한올제약주식회사 Préparation pharmaceutique
WO2010008203A2 (fr) * 2008-07-15 2010-01-21 한올제약주식회사 Preparation pharmaceutique contenant un inhibiteur des canaux calciques
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
AU2016215179B2 (en) 2015-02-06 2021-02-25 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
EP3706799B8 (fr) * 2017-11-10 2025-04-23 Op-T Llc Peptide pour la prévention, la modulation et/ou la réduction d'une maladie cardiovasculaire
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
CN114727955B (zh) * 2019-11-25 2024-03-26 福多兹制药公司 包含降脂和降血压药物的制剂
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (fr) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
ZA987843B (en) 2000-02-28
PA8457201A1 (es) 2000-05-24
IL133957A (en) 2006-06-11
YU2700A (sh) 2002-06-19
CN1117566C (zh) 2003-08-13
NZ502283A (en) 2002-05-31
BR9811558A (pt) 2000-08-22
NO20000999D0 (no) 2000-02-28
HK1029530A1 (en) 2001-04-06
DZ2600A1 (fr) 2003-03-01
ID24275A (id) 2000-07-13
PL339088A1 (en) 2000-12-04
EA002705B1 (ru) 2002-08-29
SA98190432A (ar) 2005-12-03
GT199800134A (es) 2000-02-08
WO1999011263A1 (fr) 1999-03-11
CN1268054A (zh) 2000-09-27
CA2296726A1 (fr) 1999-03-11
MA26539A1 (fr) 2004-12-20
IL133957A0 (en) 2001-04-30
HUP0003103A3 (en) 2002-03-28
AU744982B2 (en) 2002-03-07
CO4970726A1 (es) 2000-11-07
IS5345A (is) 2000-01-14
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
AU8458598A (en) 1999-03-22
NO20000999L (no) 2000-02-28
HN1998000124A (es) 1999-02-09
AP9801333A0 (en) 1998-09-30
JP2001514224A (ja) 2001-09-11
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
AR017514A1 (es) 2001-09-12
EA200000013A1 (ru) 2000-08-28
US20020025981A1 (en) 2002-02-28
KR20010022385A (ko) 2001-03-15
UY25159A1 (es) 2000-12-29
TR200000562T2 (tr) 2000-08-21
AP1207A (en) 2003-09-20
HUP0003103A2 (hu) 2001-01-29
HRP980475A2 (en) 1999-06-30
EP1003507A1 (fr) 2000-05-31
CA2296726C (fr) 2004-06-29

Similar Documents

Publication Publication Date Title
BG104076A (en) Combined treatment including amplodipin and a statine compound
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
CA2301732A1 (fr) Combinaisons therapeutiques
CA2210889A1 (fr) Inhibiteurs hydroxyethylamino contenant des bis-sulfinamides utilises pour inhiber des proteases retrovirales
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
WO1995017876A3 (fr) 2,4-disulfophenyl butylnitrone, ses sels et leur utilisation comme pieges de spin pharmaceutiques
CA2218555A1 (fr) Compositions et procedes permettant d'empecher la toxicite induite par les medicaments anti-inflammatoires non steroidiens
EP2573079A3 (fr) Dérivés de benzimidazoles quinolinones et leurs utilisations
EP2289521A3 (fr) Compositions et procédé d'utilisation pour le ciblage de la destruction vasculaire
CA2375225A1 (fr) Sel commun d'amlodipine et d'atorvastatine
PT948527E (pt) Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem
EP1559717A3 (fr) Composés d'oxabispidine et leur utilisation pour le traitement des arythmies cardiaques
CY1107763T1 (el) Εναντιομερεις ενωσεις για την αγωγη καρδιακων αρρυθμιων και μεθοδοι χρησεως
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
CA2296637A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, son procede de preparation et compositions pharmaceutiques le contenant
RU93055870A (ru) Производные бифенила, способ их получения и фармацевтическая композиция для лечения гипертонии и сердечных заболеваний
CA2375372A1 (fr) Promedicaments communs d'amlodipine et d'atorvastatine
CA2215234A1 (fr) Composition renfermant de l'amlopidine ou un sel, ou de la felodipine et un inhibiteur de l'enzyme de conversion de l'angiotensine
MX9707683A (es) Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler
MX9603300A (es) Derivados de la 4-sulfonilbenzoilguanidina o la 4-sulfinilbenzoilguanidina.
HUP9800810A2 (hu) Kombinációs terápia emberi immunhiány-vírusos (HIV) ferőzés kezelésére
UA41353C2 (uk) Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність
CA2183247A1 (fr) Korupensamines antipaludiques, compositions pharmaceutiques et utilisations medicales correspondantes
WO2000003978A3 (fr) Benzolsulfonyl-urees et -thiourees substituees en 2,5, leur procede de production, leur utilisation et les preparations pharmaceutiques les contenant